Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Debt / NOTE 3.500% 2/1
-
Market price (% of par)
-
100.64%
-
Total 13F principal
-
$111,223,000
-
Principal change
-
$0
-
Total reported market value
-
$108,345,877
-
Number of holders
-
10
-
Value change
-
-$1,574,076
-
Number of buys
-
4
-
Number of sells
-
3
Institutional Holders of INTERCEPT PHARMACEUTICALS IN - NOTE 3.500% 2/1 as of Q4 2022
As of 31 Dec 2022,
INTERCEPT PHARMACEUTICALS IN - NOTE 3.500% 2/1 was held by
10 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$111,223,000
in principal (par value) of the bond.
The largest 10 bondholders included
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Graham Capital Management, L.P., LAZARD ASSET MANAGEMENT LLC, COWEN AND COMPANY, LLC, Man Group plc, Bank of New York Mellon Corp, JPMORGAN CHASE & CO, CITIGROUP INC, AMERICAN CENTURY COMPANIES INC, and JANE STREET GROUP, LLC.
This page lists
10
institutional bondholders reporting positions
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.